 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...112113114115116117118119120121122123124 |
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma (clinicaltrials.gov) - Apr 28, 2014
P1/2, N=100, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Aug 2014 --> Aug 2013
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression (clinicaltrials.gov) - Apr 17, 2014
P2, N=133, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Aug 2014 --> Aug 2013 Trial primary completion date: Dec 2013 --> Jun 2014
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change: A Study of E7080 in Subjects With Solid Tumor (clinicaltrials.gov) - Feb 12, 2014
P1, N=9, Completed, Sponsor: Eisai Co., Ltd.
Trial primary completion date: Dec 2013 --> Jun 2014 N=18 --> 9
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: A Study of E7080 in Subjects With Solid Tumor (clinicaltrials.gov) - Feb 12, 2014
P1, N=9, Completed, Sponsor: Eisai Co., Ltd.
N=18 --> 9 Active, not recruiting --> Completed
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial termination: A Study in Subjects With Recurrent Malignant Glioma (clinicaltrials.gov) - Dec 19, 2013
P2, N=152, Terminated, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, Combination therapy, Metastases: E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma (clinicaltrials.gov) - Nov 13, 2013
P1/2, N=100, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Terminated Initiation date: Mar 2010 --> Dec 2012
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: An Open Label Dose Escalation Study Of E7080 (clinicaltrials.gov) - Nov 13, 2013
P1, N=82, Active, not recruiting, Sponsor: Eisai Inc.
Initiation date: Mar 2010 --> Dec 2012 Completed --> Active, not recruiting
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Combination therapy, Metastases: A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment (clinicaltrials.gov) - Aug 21, 2013
P1/2, N=180, Active, not recruiting, Sponsor: Eisai Inc.
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung (clinicaltrials.gov) - Jun 11, 2013
P2, N=1000, Recruiting, Sponsor: Eisai Co., Ltd.
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change: REFLECT: A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 3, 2013
P3, N=940, Recruiting, Sponsor: Eisai Limited
Recruiting --> Active, not recruiting N=1450 --> 940
- |||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: REFLECT: A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - May 5, 2013
P3, N=940, Recruiting, Sponsor: Eisai Limited
N=1450 --> 940 Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: E7080 Food Effect Study in Healthy Subjects (clinicaltrials.gov) - Mar 2, 2013
P1, N=16, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments (clinicaltrials.gov) - Feb 26, 2013
P2, N=135, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial: REFLECT: A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 2, 2013
P3, N=940, Recruiting, Sponsor: Eisai Limited
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial termination, Combination therapy: E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 (clinicaltrials.gov) - Jan 1, 2013
P1/2, N=7, Terminated, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; poor accrual
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - Dec 5, 2012
P2, N=182, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Terminated; poor accrual Recruiting --> Active, not recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: A Study of E7080 in Subjects With Advanced Thyroid Cancer (clinicaltrials.gov) - Nov 18, 2012
P2, N=16, Recruiting, Sponsor: Eisai Co., Ltd.
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) (clinicaltrials.gov) - Oct 3, 2012
P3, N=392, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression (clinicaltrials.gov) - Sep 10, 2012
P2, N=133, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Combination therapy, Metastases: A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma (clinicaltrials.gov) - Jun 28, 2012
P1, N=115, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Metastases: E7080-J081-202: Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - May 13, 2012
P1/2, N=66, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Completed N=11 --> 66
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: E7080-J081-202: Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - May 13, 2012
P1/2, N=66, Active, not recruiting, Sponsor: Eisai Co., Ltd.
N=11 --> 66 Recruiting --> Active, not recruiting
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Combination therapy, Metastases: E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma (clinicaltrials.gov) - Apr 9, 2012
P1/2, N=100, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments (clinicaltrials.gov) - Feb 6, 2012
P2, N=135, Active, not recruiting, Sponsor: Eisai Inc.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval (clinicaltrials.gov) - Jan 31, 2012
P1, N=52, Completed, Sponsor: Eisai Inc.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Combination therapy: E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 (clinicaltrials.gov) - Jan 5, 2012
P1/2, N=7, Terminated, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting N=100 --> 7
- |||| golvatinib (E7050) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Combination therapy, Metastases: A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) (clinicaltrials.gov) - Nov 3, 2011
P1/2, N=226, Recruiting, Sponsor: Eisai Inc.
N=100 --> 7 Not yet recruiting --> Recruiting
- ||||| golvatinib (E7050) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial, Combination therapy, Metastases: A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) (clinicaltrials.gov) - Sep 12, 2011
P1/2, N=226, Recruiting, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Combination therapy: E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Aug 10, 2011
P1, N=33, Completed, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed